

Human ALK-1/ACVRL1 Protein

Cat. No. ALK-HM201



Description

Source	Recombinant Human ALK-1/ACVRL1 Protein is expressed from HEK293 with hFc (IgG1) tag at the C-terminus.
	It contains Asp22-Gln118.
Accession	P37023
Molecular Weight	The protein has a predicted MW of 36.65 kDa. Due to glycosylation, the protein migrates to 65-85 kDa based on Bis-Tris PAGE result.
Endotoxin	Less than 0.1 EU per µg by the LAL method.
Purity	> 95% as determined by Bis-Tris PAGE
	> 95% as determined by HPLC

Formulation and Storage


Formulation	Lyophilized from 0.22 µm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution	Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Storage	-20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Background

Activin receptor-like kinase 1 (ALK1)-mediated endothelial cell signalling in response to bone morphogenetic protein 9 (BMP9) and BMP10 is of significant importance in cardiovascular disease and cancer. Structural analyses reveal a tripartite recognition mechanism that defines BMP9 and BMP10 specificity for ALK1, and predict that crossveinless 2 is not an inhibitor of BMP9, which is confirmed by experimental evidence.


Assay Data

Bis-Tris PAGE



Human ALK-1 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC




The purity of Human ALK-1 is greater than 95% as determined by SEC-HPLC.

Assay Data

ELISA Data

Human ALK-1, hFc Tag ELISA

0.1µg Human GDF-2, No Tag Per Well



Immobilized Human GDF-2, No Tag (Cat. GDF-HM002) at 1µg/ml (100µl/well) on the plate. Dose response curve for Human ALK-1, hFc Tag with the EC50 of 8.5ng/ml determined by ELISA.